In order to enter into a therapy management contract, a pharmacist: Shall be licensed by and in good standing with the Board of Pharmacy; Shall possess a Doctor of Pharmacy degree or equivalent training as established in §B of this regulation; May not have: A public final order by the Board of Pharmacy disciplining the pharmacist's license within the 5 years immediately before the application is submitted; or Limitations placed on the pharmacist's license by the Board of Pharmacy in a public order; Shall possess relevant advanced training as indicated by one of the following: Certification as a specialist related to the disease state specified by the protocol by: The Board of Pharmacy Specialties; The American Society of Consultant Pharmacist's Certified Geriatric Practitioner certification program; or Another credentialing body approved by the Board of Pharmacy; or Successful completion of: A residency accredited by the American Society of Health-Systems Pharmacists, a body approved by the Board of Pharmacy or offered by a body accredited by the Accreditation Council for Pharmacy Education; A certificate program approved by the Board of Pharmacy; A National Association of Boards of Pharmacy credentialing examination; or An examination approved by the Board of Pharmacy; Shall have successfully completed: 1,000 hours of relevant clinical experience; or 320 hours in a structured experience program approved by the Board of Pharmacy; and Shall document training related to the disease state specified in the protocol. A pharmacist who does not possess a Doctor of Pharmacy degree shall document that the pharmacist's training has included the following components: Designing, implementing, monitoring, evaluating, and modifying or recommending modifications in drug therapy to insure effective, safe, and economical patient care; Identifying, assessing, and solving medication-related problems, and providing clinical judgments as to the continuing effectiveness of individualized therapeutic plans and intended therapeutic outcomes; Conducting appropriate physical assessments, evaluating patient problems, and ordering and monitoring medications and laboratory tests in accordance with established standards of practice; Monitoring patients and patient populations regarding the purposes, uses, effects, and pharmacoeconomics of their medications and related therapy; Providing emergency first care, including cardiopulmonary resuscitation; Using clinical data to optimize therapeutic drug regimens; and Documenting interventions and evaluating pharmaceutical care outcomes. The Board of Pharmacy shall determine whether the pharmacist meets the requirements of §§A and B of this regulation. An authorized prescriber who has entered into a prescriber-pharmacist agreement shall submit to the Boards that regulate the authorized prescriber a copy of: The prescriber-pharmacist agreement; Subsequent amendments made to the: Prescriber-pharmacist agreement; or Protocols specified in the prescriber-pharmacist agreement; and Changes to participants of the: Prescriber-pharmacist agreement; or Protocols specified in the prescriber-pharmacist agreement. The Boards that regulate the authorized prescriber shall notify the authorized prescriber of any additional information needed within 30 days of the receipt of the submitted information. A licensed pharmacist who has entered into a prescriber-pharmacist agreement shall submit to the Board of Pharmacy a copy of: The prescriber-pharmacist agreement; Subsequent amendments made to the: Prescriber-pharmacist agreement; or Protocols specified in the prescriber-pharmacist agreement; and Changes to participants of the: Prescriber-pharmacist agreement; or Protocols specified in the prescriber-pharmacist agreement. The Board of Pharmacy shall determine whether a pharmacist added under §F of this regulation meets the requirements of §§A and B of this regulation. The Board of Pharmacy shall notify the pharmacist of any additional information needed within 30 days of the receipt of the submitted information.